Incidence and risk factors for venous thromboembolism in the Cancer-VTE Registry pancreatic cancer subcohort.
Incidence
Mortality
Pancreatic cancer
Risk factors
Venous thromboembolism
Journal
Journal of gastroenterology
ISSN: 1435-5922
Titre abrégé: J Gastroenterol
Pays: Japan
ID NLM: 9430794
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
received:
23
03
2023
accepted:
07
08
2023
medline:
21
11
2023
pubmed:
7
9
2023
entrez:
7
9
2023
Statut:
ppublish
Résumé
This substudy of the Cancer-VTE Registry estimated venous thromboembolism (VTE) incidence and risk factors in pancreatic cancer patients. The Cancer-VTE Registry was an observational study that collected VTE data from patients with solid tumors across Japan. We measured baseline VTE prevalence, and at 1-year follow-up, the cumulative incidence of symptomatic and composite VTE (symptomatic VTE and incidental VTE requiring treatment), bleeding, cerebral infarction/transient ischemic attack (TIA)/systemic embolic event (SEE), and all-cause death. Of 1006 pancreatic cancer patients, 86 (8.5%) had VTE at baseline, and seven (0.7%) had symptomatic VTE. Significant risk factors of baseline VTE were Eastern Cooperative Oncology Group performance status (ECOG PS) of 1, body mass index (BMI) ≥ 25 kg/m The cumulative incidence of composite VTE during cancer treatment was higher in pancreatic cancer than in other cancer types. Some risk factors for VTE prevalence at cancer diagnosis were identified. Although VTE prevalence at cancer diagnosis did not predict the subsequent 1-year incidence of composite VTE, it was a significant predictor of other events such as all-cause death in pancreatic cancer patients. UMIN Clinical Trials Registry; UMIN000024942.
Sections du résumé
BACKGROUND
This substudy of the Cancer-VTE Registry estimated venous thromboembolism (VTE) incidence and risk factors in pancreatic cancer patients.
METHODS
The Cancer-VTE Registry was an observational study that collected VTE data from patients with solid tumors across Japan. We measured baseline VTE prevalence, and at 1-year follow-up, the cumulative incidence of symptomatic and composite VTE (symptomatic VTE and incidental VTE requiring treatment), bleeding, cerebral infarction/transient ischemic attack (TIA)/systemic embolic event (SEE), and all-cause death.
RESULTS
Of 1006 pancreatic cancer patients, 86 (8.5%) had VTE at baseline, and seven (0.7%) had symptomatic VTE. Significant risk factors of baseline VTE were Eastern Cooperative Oncology Group performance status (ECOG PS) of 1, body mass index (BMI) ≥ 25 kg/m
CONCLUSIONS
The cumulative incidence of composite VTE during cancer treatment was higher in pancreatic cancer than in other cancer types. Some risk factors for VTE prevalence at cancer diagnosis were identified. Although VTE prevalence at cancer diagnosis did not predict the subsequent 1-year incidence of composite VTE, it was a significant predictor of other events such as all-cause death in pancreatic cancer patients.
TRIAL REGISTRATION
UMIN Clinical Trials Registry; UMIN000024942.
Identifiants
pubmed: 37676492
doi: 10.1007/s00535-023-02033-3
pii: 10.1007/s00535-023-02033-3
pmc: PMC10657787
doi:
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1261-1271Informations de copyright
© 2023. The Author(s).
Références
Cancer Med. 2022 Apr;11(7):1605-1616
pubmed: 35148464
Thromb Res. 2009;123 Suppl 4:S11-7
pubmed: 19303496
JACC CardioOncol. 2021 Apr 20;3(2):173-190
pubmed: 34396323
J Cardiol. 2015 Dec;66(6):451-9
pubmed: 25896176
JTO Clin Res Rep. 2022 Aug 08;3(9):100392
pubmed: 36089919
Oncotarget. 2018 Mar 30;9(24):16883-16890
pubmed: 29682191
J Hematol. 2019 Mar;8(1):17-25
pubmed: 32300436
Circ J. 2011;75(5):1258-81
pubmed: 21441695
Br J Cancer. 2022 Dec;127(12):2099-2107
pubmed: 36097177
Gastroenterology. 2020 Apr;158(5):1346-1358.e4
pubmed: 31843588
J Formos Med Assoc. 2022 Jan;121(1 Pt 2):360-366
pubmed: 33994235
Int J Hematol. 2008 Apr;87(3):250-5
pubmed: 18283526
PLoS Med. 2012;9(7):e1001275
pubmed: 22859911
Cancer Sci. 2021 Nov;112(11):4679-4691
pubmed: 34382298
Arterioscler Thromb Vasc Biol. 2018 Apr;38(4):709-725
pubmed: 29437578
Jpn J Clin Oncol. 2020 Oct 22;50(11):1246-1253
pubmed: 32715307
Thromb Res. 2022 May;213:203-213
pubmed: 35282898
Blood. 2008 May 15;111(10):4902-7
pubmed: 18216292
J Thromb Haemost. 2007 Mar;5(3):632-4
pubmed: 17319909
J Thromb Haemost. 2017 Aug;15(8):1567-1575
pubmed: 28585779
J Med Ultrason (2001). 2008 Mar;35(1):33-6
pubmed: 27278564
J Clin Oncol. 2009 Oct 10;27(29):4839-47
pubmed: 19720906
Blood. 2021 Apr 8;137(14):1959-1969
pubmed: 33171494
Blood. 2007 Sep 15;110(6):1723-9
pubmed: 17496204
Blood Adv. 2022 Jan 11;6(1):307-320
pubmed: 34649273
Transl Res. 2014 Feb;163(2):145-50
pubmed: 23973167
Cancer Sci. 2022 Nov;113(11):3901-3911
pubmed: 35947508
Cancer. 2007 Nov 15;110(10):2339-46
pubmed: 17918266
BMJ Open. 2018 May 30;8(5):e018910
pubmed: 29848769
PLoS One. 2022 Mar 1;17(3):e0264653
pubmed: 35231078
Thromb Res. 2014 May;133 Suppl 2:S39-43
pubmed: 24862144
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211051766
pubmed: 34730013